Variational AI

Generative AI foundation model (Enki) for small-molecule drug discovery.

Variational AI, headquartered in Vancouver, British Columbia, Canada, is building Enki, a generative AI foundation model for small-molecule drug discovery intended to design novel, selective, drug-like molecules across many targets. The company raised an oversubscribed seed financing of $5.5M to launch the model and works with drug discovery partners. Atlas found no vendor-held security certifications documented on its site.

Headquarters
Vancouver, Canada
Deployment options
cloud
Website
https://variational.ai
LinkedIn
https://www.linkedin.com/company/variational-ai

Categories

AI Use Cases

  • ADMET & Toxicity Prediction
  • Hit Identification & Lead Optimization

Vendor Scorecard

50% — Partial coverage. Coverage score — how completely Atlas documents Variational AI across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.

Compliance & Validation — Not documented by Atlas

Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?

Deployment & Hosting — Documented

cloud

Pricing Transparency — Not documented by Atlas

Ask the vendor: What is your pricing model, and what drives total cost of ownership?

Implementation & Onboarding — Not documented by Atlas

Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?

Organization & Role Fit — Documented

Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery

Solution Scope — Documented

ADMET Prediction, Molecular Generation

Company Viability — Partially documented

Seed

Always ask the vendor

Not captured in Atlas data — confirm directly. Excluded from the score above.

Data Rights & IP

Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?

Model Credibility & Explainability

Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?

Questions to Ask This Vendor

  • What retrospective benchmarks demonstrate Enki's generation quality and selectivity?
  • Which target classes are best supported by the foundation model today?
  • How is IP ownership handled for generated molecules?
  • What engagement models are available for our discovery programs?